Reading the tape
NYSE: AZN
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
Market Cap
$283.47B
52w High
$212.71
52w Low
$132.32
P/E
26.88
Volume
1.18M
Outstanding Shares
1.55B
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
1Y Price: 36.35%Revenue (TTM): 9.93%FCF (TTM): -5.88%P/FCF: 25th pct
What changed
The stock rose 36.35% over the last year. Revenue grew 9.93% over the trailing twelve months. Operating margin moved from 19.21% to 23.69%. Free cash flow declined 5.88% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 25th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 23.69%. Revenue grew 9.93% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 5.88%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
CEOPascal Claude Roland Soriot
SectorHealthcare
IndustryDrug Manufacturers - General
Employees94,300
IPO dateMay 12, 1993
Valuation
Forward P/E—
EV/EBITDA14.93
Enterprise value$296.02B
Stock splits
Feb 2, 2026↓ Reverse
Every 2 shares became 1
Jul 27, 2015↑ Forward
Every 1 shares became 2
Apr 8, 1998↑ Forward
Every 1 shares became 3
Profitability & growth
Revenue growth12.51%
Gross margin79.71%▲0.95%vs FY2024
Operating margin23.53%▲26.48%vs FY2024
ROE21.07%▲22.17%vs FY2024
Analyst consensus
RatingBuy
Target price$211.00▲15.40%
20
Buy
15
Hold
6
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jul 27, 2026
Q3 FY26 · EPS est $2.27 · Revenue est $15.44B
View
Dividends
$3.20/shareSemi-annualSafeAZN pays a dividend with a 1.75% dividend yield, growing at 2.32% annually, covered 2.3× by free cash flow.
Dividend Yield
1.75%
Annual Div / Share
$3.20
5yr CAGR
+2.32%
Doubles every ~30.2yr
Payout Ratio
46.98%
Safe
Dividend Growth Rate
3yr CAGR
+3.31%
5yr CAGR
+2.32%
10yr CAGR
+1.34%
Dividend Safety
9/10Safe
Dividend History
Annualized dividend cycles per share
YearAnnual DivYoY
2026$3.20+2.3%
2025$3.13+7.9%
2024$2.90-0.1%
2023$2.90+1.2%
2022$2.87+0.5%
2021$2.85+3.5%
2020$2.76-1.5%
Income Projection
Invest
$
Growth rate:
Reinvest dividends
Today
$18/yr
$1/mo
In 5 yrs
$20/yr+12%
$2/mo
In 10 yrs
$22/yr+26%
$2/mo
| Today | In 5 yrs | In 10 yrs |
|---|---|---|
$18/yr $1/mo | $20/yr+12% $2/mo | $22/yr+26% $2/mo |
Yield-on-cost grows from 1.75% → 2.2% over 10yr
Analysis
Dividend Strengths
Well-covered by free cash flow
The dividend is covered 2.3× by free cash flow, indicating the company generates sufficient cash to sustain and potentially grow the payout without straining its finances.
Risks to Watch
No strong risk signal stands out from the latest period pair.